Material and Method: Medical records of adults who underwent a kidney biopsy procedure in our institution between January 2000 and June 2019 were reviewed. Pathology reports were searched for biopsies where a granuloma was identified.
Results: Nineteen of 1121 (1.7%) kidney biopsies included granuloma, 17 in native kidneys, and 2 in transplants. The majority of indications for native kidney biopsy was a rise in serum creatinine. Etiologies of granuloma included the following: pauci-immune vasculitis (n=11, 64.7%), tuberculosis (n=2, 11.8%), drug-induced (n=2, 11.8%), tubulointerstitial nephritis/uveitis (TINU) syndrome (n=1, 5.9%), and systemic-lupus erythematosus (n=1, 5.9%). Despite treatment, 6 of 11 (54.5%) patients with vasculitis developed end-stage kidney disease (ESKD) during the median follow-up of 16 months. Both of the patients with tuberculosis, and the patient with TINU syndrome developed ESKD months after the kidney biopsy, despite appropriate therapies. The only case with drug-induced granuloma and both cases with allograft kidney granuloma responded well to glucocorticoids, achieving a complete renal recovery.
Conclusion: The majority of our series had granuloma in the kidney secondary to vasculitis and renal outcomes appear considerably unfavorable despite treatment, probably related to the primary diagnosis. Multicenter studies are needed to better determine the etiology and outcome of each granuloma etiology at different geographic locations.
It is not straightforward to differentiate between these causes using renal histology alone, and the diagnosis is usually made based on the clinical presentation and extrarenal findings [29,30]. The most common cause differs between geographical regions. Drug-induced GIN and renal involvement of sarcoidosis are quite common along with idiopathic GIN in Western countries [31,32], whereas tuberculosis is the most common cause of GIN in endemic areas such as India [12,13].
The number of studies on granuloma/granulomata formation in kidney is quite limited. Despite the endemicity of tuberculosis, there is no data on the prevalence of GIN in Turkey. We therefore aimed to investigate the causes of granuloma formation in the kidney and analyze long-term outcomes of these patients.
The date of kidney biopsy was recorded as the baseline for laboratory records. Acute kidney injury was defined according to consensus criteria [33]. Rapidly progressive glomerulonephritis was defined as the loss of kidney function within days to weeks along with remarkable findings in urinalysis [34]. Microscopic hematuria was accepted if >3 red blood cells per high power field were seen in urine microscopy [35]. End-stage kidney disease (ESKD) was defined according to consensus criteria [36]. Given that the majority of cases presented with a rise in serum creatinine, the definition of response to therapy was made as follows. Complete response was a return of serum creatinine to <0.35 mg/dL above the baseline value and partial response was a return of serum creatinine to >.0.35 mg/dL but less than twice the baseline value [37].
Renal Histopathology
Histological data was retrieved from pathology
reports. Renal biopsy specimens were evaluated using
hematoxylineosin, Massons trichrome, periodic acid
schiff, and methenamine silver stained sections by light
microscopy. Immunofluorescent analysis was made after staining for antibodies against immunoglobulins G-A-M,
complement components C3 and C1q, and kappa and
lambda light-chains for immunofluorescence. Electron
microscopic evaluation was not routinely performed.
Previous studies used the term GIN if at least 1 granuloma
in kidney sections was found [32]. For this study, we have
used the term granuloma/granulomata formation since
there is no consensus for the definition of GIN. Given
that tuberculosis is endemic in our country, Ziehl-Neelsen
staining was performed on kidney sections of patients with
a history of pulmonary tuberculosis, on allograft kidney
with granulomatous inflammation, and on patients with
no identified cause of granuloma formation.
Statistical Analysis
Quantitative variables were expressed as median with
the range (minimum-maximum). Qualitative variables
were expressed as proportions. Overall renal survival was
estimated using the Kaplan-Meier method. Statistical
analysis was performed using SPSS 22.0 version (IBM
SPSS, Chicago, IL).
Native Kidney Granuloma/Granulomata
Of the 17 native kidney granulomata, 11 (64.7%) were male
and the median age was 60 (range, 21-84). At baseline,
hypertension and diabetes mellitus constituted 52.9% (9
patients) and 29.4% (5 patients) of the cohort. Indications
for kidney biopsy included acute kidney injury (AKI) in 12
(70.6%), rapidly progressive glomerulonephritis (RPGN)
in 4 (23.5%), and asymptomatic urinary abnormalities
in 1 (5.9%) case. The following etiologies were captured
after the detailed evaluation: pauci-immune vasculitis
(n=11, 64.7%), tuberculosis (n=2, 11.8%), drug-induced
(n=2, 11.8%), tubulointerstitial nephritis/uveitis (TINU)
syndrome (n=1, 5.9%), and systemic-lupus erythematosus
(n=1, 5.9%). Detailed description of each native kidney
granuloma is given in Table I.
Pauci-Immune Vasculitis
The median age of these patients was 60 (range, 28-84), and
7 (63.6%) were male. Clinical presentations were as follows:
AKI (6 patients, 54.5%), RPGN (4 patients, 30.8%), and asymptomatic urinary abnormalities (1 patient, 7.7%). The
median serum creatinine at baseline was 4.46 (range, 1.69-
9.87) mg/dL. Six patients required hemodialysis at the time
of diagnosis. Seven of these had positive antibodies against
myeloperoxidase (MPO-ANCA), and 4 had positive
antibodies against proteinase-3 (PR3-ANCA). All of these
patients were pauci-immune based on immunofluorescence
microscopy findings. Lung involvement was evident in 5
(38.5%) of patients. Histology was remarkable for severe
necrotizing granulomatous inflammation with crescent
formation in the majority (Figure 1). All subjects received
glucocorticoids while some were also treated with a mixture
of cyclophosphamide, plasma exchange, azathioprine,
and/or mycophenolate mofetil. Among the 10 patients
who presented with AKI or RPGN, 6 had no response, 2
had partial response, and 2 achieved a complete response.
The patient who had asymptomatic urinary abnormalities
did not receive immunosuppressive therapy and findings
in urine persisted following therapy with angiotensinconverting
enzyme inhibitor. During the median follow-up
of 16 (range, 1-84) months, 6 (54.5%) patients developed
ESKD and 2 (18.2%) of them died.
Tuberculosis
Two patients had tuberculosis of the kidney. Both subjects
already had a diagnosis of tuberculosis of the lung by
polymerase chain reaction and sputum culture prior to
kidney biopsy.
The first patient was a 74-year-old-male with long-standing hypertension. The clinical presentation was AKI, with a serum creatinine level of 2.3 mg/dL. Kidney functions deteriorated and hemodialysis was initiated. There was a history of lung tuberculosis and Ziehl-Neelsen staining was positive in the kidney. In addition to severe necrotizing granulomatous inflammation, there was also crescent formation in the histology. A subsequent bone marrow biopsy also showed severe granulomatous inflammation.
The patient received a combination of rifampin, isoniazide, ethambutol, and pyrazinamide, but could not come off dialysis. Unfortunately, the patient died 3 months after the kidney biopsy.
Indication for kidney biopsy in the second patient, a 50-year-old male, was AKI, with a serum creatinine of 3.32 mg/dL. Nephrotic syndrome was also evident, with 7.9 grams/24 hours of urinary protein excretion. Kidney biopsy showed severe necrotizing granulomatous intersitial nephritis. The same treatment protocol was given for tuberculosis. Unfortunately, the patient developed ESKD within 3 months after the kidney biopsy. Although both cases had a rise in serum creatinine after hospitalization, baseline serum creatinine levels were not known. They were both HIV-negative. Kidney histology revealed moderate to severe interstitial fibrosis/tubular atrophy, suggesting a preceding chronic damage.
Tubulointerstitial Nephritis/Uveitis (TINU) Syndrome
The patient with TINU syndrome was a 21-year-oldmale,
who was admitted to the hospital for allopecia
totalis, red eye, and malaise. Examination of the eye was
compatible with anterior uveitis. Serum creatinine was 3.3
mg/dL and proteinuria was subnephrotic. Urine sediment
showed pyuria but no microhematuria. Serological workup
was unremarkable. Kidney histology showed severe
tubulointerstitial granulomatous inflammation with mild
interstitial fibrosis and crescent formation. There was
non-necrotizing granulomatous inflammation (Figure
2). Following treatment with cyclophosphamide and
glucocorticoids, the alopecia and uveitis completely
resolved with a mild improvement in kidney functions.
However, kidney functions deteriorated during the
following year requiring permanent dialysis, despite
therapy with mycophenolate mofetil, rituximab, and
intravenous immunoglobulin.
Drug-Induced GIN
The first patient with drug-induced GIN, a 72-year-old
woman, presented with AKI. Abnormal test results included
a serum creatinine of 2.8 mg/dl with mild (<1 g/day)
proteinuria and pyuria, but no microhematuria. Penicillin
was given for upper respiratory tract infection a week before
the AKI event. Kidney biopsy showed granulomatous
inflammation and mild interstitial fibrosis and tubular
atrophy (IFTA). Work-up for possible other etiologies such
as tuberculosis, sarcoidosis, and inflammatory rheumatic
diseases were unremarkable. Glucocorticoids provided
a complete remission with no further relapse during the
following 63 months of follow-up.
The second patient was a 62-year-old male with longstanding hypertension and diabetes. The presentation was AKI, with a serum creatinine of 3.74 mg/dL, which climbed from a baseline of 1.5 mg/dL. Urine sediment was active and the kidney biopsy showed severe necrotizing granulomatous interstitial nephritis with multiple multinucleated giant cells, and crescent formation. A detailed work-up including ANA and ANCA tests, serum calcium, hepatitis serology, ACE levels, and chest CT were unremarkable. The patient stated that he received daily non-steroid anti-inflammatory drugs within the last 2 weeks for headache. Due to crescents in histology, the patient received a combination of corticosteroids and cyclophosphamide. Unfortunately, he developed ESKD with no response to therapy during the follow-up of 6 months.
Systemic Lupus Erythematosus
This was a 50-year-old woman with a history of chronic
polyarthritis in small joints of the hand. Her presentation
was with AKI, with a serum creatinine of 2.61 mg/dL.
Baseline serum creatinine was told to be normal. There was
approximately 3 g/24 hours of urinary protein excretion,
but no hematuria. A kidney biopsy showed severe
necrotizing granulomatous interstitial nephritis with
crescent formation. Immunofluorescence was negative
for immunoglobulins and complement. ANA and Antidouble
stranded DNA (Anti-dsDNA) results were positive.
Induction immunosuppression included corticosteroid
and cyclophosphamide. The patient had partial response
and she was maintained with azathioprine. After partial
response, kidney functions remained stable with no further
relapse during the follow-up of 52 months.
Among all patients with native kidney granuloma formation, the median follow-up was 24 months. Ten (58.8%) patients developed ESKD, and 4 (23.4%) died. Overall, the median estimated renal survival of 17 patients with granuloma/granulomata in the native kidney was 12 months.
Granuloma in the Allograft Kidney
The first patient with granuloma in the allograft kidney,
a 49-year-old female, had allograft dysfunction 7 years
after the kidney transplantation. The primary etiology of
ESKD was chronic pyelonephritis. Serum creatinine during
allograft biopsy was 1.1 mg/dL, which increased from a
baseline of 0.7 mg/dL. Urine tests showed a subnephrotic
proteinuria and microhematuria. Biopsy showed
granulomatous inflammation with crescents. There was
no lung or upper respiratory-tract involvement. Detailed
work-up including ANCA tests and other autoantibodies
were all negative. Following glucocorticoid therapy (1 mg/
kg), she achieved a complete remission with the serum
creatinine returning to baseline levels around 0.7 mg/
dl. Renal function remained stable for the following 68
months.
The second patient with granuloma in the allograft kidney was a 20-year-old male. He presented with a rising serum creatinine, from 1.2 mg/dL to 2.67 mg/dL. This was 11 years after the kidney transplantation and the primary etiology of the ESKD was chronic glomerulonephritis. Native kidney biopsy was compatible with immunecomplex glomerulonephritis (including C1q positivity on immunofluorescence microscopy) but no granuloma, ANA and ANCA tests were negative. After a detailed evaluation, the cause of granuloma formation could not be found, and the etiology was deemed to be idiopathic. With the introduction of 1 mg/kg of glucocorticoids and continuation of mycophenolate mofetil with calcineurininhibitor, he achieved a complete response with a serum creatinine returning close to the baseline levels of 1.4 mg/ dL.
Previous reports included several cases with sarcoidosis of the kidney [38]; yet we have not observed any, despite detailed diagnostic tests such as angiotensin-converting enzyme levels, computed tomography, and bronchoscopy were performed. Excluding 2 cases of drug-induced GIN and 2 allograft biopsies, more than half of our patients developed ESKD. This is probably be due to the high frequency of glomerulonephritis with crescents in our cohort and low number of cases with drug-induced GIN and absence of sarcoidosis, rather than granuloma formation itself. Thus, diseases causing acute granulomatous inflammation in the kidney, which may respond better to treatment were less frequently observed in our cohort. Indeed, Zajjari et al. stated that the outcome was good in patients with drug-induced GIN or sarcoidosis [39]. In contrast to the outcomes of our patients, Joss et al. reported quite acceptable renal response to therapies [32]. However, the authors excluded cases with crescents from their study, as these were accepted as secondary GIN. We have not excluded these subjects, since GIN frequently occurs secondary to a systemic disease such as autoimmune disorders or particular infections. Crescent formation was also evident in one of our patients with tuberculosis and the one with TINU syndrome, which would be another argument to support the inclusion of patients with crescents.
Crescent formation with granulomatous inflammation is characteristic of granulomatous polianjitis (GPA), yet granulomatous inflammation is frequently seen in lung biopsies rather than kidney specimens [40]. It is not known whether renal survival is worse among subjects with GPA who have granulomatous inflammation in the kidney versus GPA without renal granulomatosis. This issue requires further study. In a multicenter study, kidney biopsies of patients with pauci-immune crescentic glomerulonephritides were classified according to the extent of the lesions in the Bowman space, and the authors used the term full moon for those who had circumferential crescents [41]. The main message of the paper was that patients with full moon crescents had more unfavorable renal survival. Interestingly, granuloma formation was more common in patients with full moon crescents. Among the pauci-immune glomerulonephritides, GPA and eosinophilic GPA are known to cause granulomatous inflammation. Although ANCA against proteinase (c-ANCA) is usually the positive antibody found in GPA, p-ANCA positivity was more common in this cohort.
Another typical chronic disease that may cause granulomatous inflammation in the kidney is tuberculosis. Renal tuberculosis is easily overlooked, and the diagnosis sometimes made post-mortem [42]. The unfavorable outcomes of our 2 cases with renal tuberculosis may be due to the delayed diagnosis. Moreover, despite a high index of clinical suspicion, the diagnosis of GIN secondary to tuberculosis may be difficult and require PCR-based techniques [43]. Microorganisms may not be detected in histological examination of the kidney. Ziehl-Neelsen staining helped only in 1 of 9 cases in the study by Agrawal and co-workers [43]. The Ziehl-Neelsen stain result was positive in 1 of 2 our cases with tuberculosis. Some authors recommend combining the auramine O stain in order to increase sensitivity and specificity for the detection of tuberculosis [44]. Timely diagnosis and early treatment of tuberculosis is associated with more favorable outcomes [42]. GIN due to tuberculosis is even more common among subjects infected with HIV, and is associated with increased mortality in that case [45]. None of our cases were HIVpositive. Similar to our paper, tuberculosis was not the predominant etiology in some of the previous reports from endemic locations [46].
One chronic systemic inflammatory disease causing GIN is the TINU syndrome. The presentation as GIN is quite rare for this syndrome [30]. The presence of a crescent in our patient with TINU is also unusual. Another unexpected thing in our case is the unfavorable outcome, despite the prescription of a mixture of immunosuppressive drugs including glucocorticoids, cyclophosphamide, and rituximab. The patient uneventfully developed ESKD and was maintained on hemodialysis. Our case is the exception rather than the rule, and more studies are needed to delineate the prognostic impact of TINU syndrome on kidney outcomes.
Similar to native kidney GIN, the etiological factors are numerous in allograft kidney GIN, including several acute and chronic disorders. Infections are the most common cause of GIN in allograft kidneys [47]. For transplant patients, it is important to determine if the etiology of ESKD recurs after kidney transplantation. Data for transplant kidney GIN are more lacking and come from case reports (Table II). It is not clear if GIN recurs after kidney transplantation. However, recurrences of sarcoidosis [48], idiopathic GIN [49], TINU [50,51], and crescentic GN [47] were reported. The potential to recur probably depends on the etiology but the majority of case reports and the data from our study indicate a favorable survival in most patients, although some developed graft loss. Concurrent rejection episodes may occur and contribute to graft failure in some patients with GIN [52].
Table II: Reports of Granulomatous Interstitial Nephritis in Allograft Kidneys
Our study contains a number of limitations. This was a descriptive study with a small sample size, and etiologies of renal granuloma were determined retrospectively. In the majority of our cases, GIN was probably caused by chronic kidney damage, and it may not be reasonable to compare outcomes of acute causes of GIN versus those with subacute/chronic damage. Despite these significant limitations however, there are only a few studies on GIN and our data shows the considerably unfavorable renal survival of patients, unlike previous case series (Table III). This is particularly the case for patients with chronic causes GIN, such as GPA. All of our cases had granuloma/ granulomata formation but it is not clear if all of them should be regarded as GIN. There is no consensus for the definition of GIN, and this issue should be studied. Effects of granuloma formation on kidney outcomes may not be the same for each etiology, and it may not be straightforward to use a common definition for all. Apparently, acute and chronic causes of GIN should be separately evaluated.
Table III: Previous Studies on Native Kidney Granulomatous Interstitial Nephritis
In conclusion, ANCA-associated vasculitis appeared to be the most common cause of granuloma formation in the kidney in our study. Renal survival is significantly shortened and multicenter studies are needed in order to delineate the nature of different etiologies of granuloma formation in the kidney, and determine the best treatment option for each category.
CONFLICT of INTEREST
The authors declare no conflict of interest.
ETHICS APPROVAL
This study was approved by the Ethics Committee of Dokuz
Eylül University Medical School (IRB code: 2019/17-
230307).
INFORMED CONSENT
Informed consent was waived due to the retrospective
design, confidentiality of patient identity, and absence of
any invasive procedures.
AUTHORSHIP CONTRIBUTIONS
Concept: CH, BDY, MAO, SS, Design: CH, Data collection
or processing: CH, BDY, MÜ, HÜA, ÖU, FY, SY, Analysis
of Interpretation: CH, BDY, MÜ, HÜA, ÖU, FY, SY, MAO,
AÇ, AS, CÇ, SS, Literature search: CH, BDY, Writing: CH,
BDY, SS, Approval: CH, BDY, MÜ, HÜA, ÖU, FY, SY,
MAO, AÇ, AS, CÇ, SS.
1) Shah S, Carter-Monroe N, Atta MG. Granulomatous interstitial
nephritis. Clin Kidney J. 2015;8:516-23.
2) ORiordan E, Willert RP, Reeve R, Kalra PA, ODonoghue DJ,
Foley RN, Waldek S. Isolated sarcoid granulomatous interstitial
nephritis: Review of five cases at one center. Clin Nephrol. 2001;
55:297-302.
3) Robson MG, Banerjee D, Hopster D, Cairns HS. Seven cases of
granulomatous interstitial nephritis in the absence of extrarenal
sarcoid. Nephrol Dial Transplant. 2003;18:280-4.
4) Tsukada H, Shimizu H, Kaname S. Bilateral nephromegaly due to
isolated renal sarcoidosis. Clin Exp Nephrol. 2017;21:169-70.
5) Utas C, Dogukan A, Patiroglu TE, Oymak S, Oymak O.
Granulomatous interstitial nephritis in extrapulmonary
sarcoidosis. Clin Nephrol. 1999;51:252-4.
6) Timmermans SA, Christiaans MH, Abdul-Hamid MA, Stifft
F, Damoiseaux JG, van Paassen P. Granulomatous interstitial
nephritis and Crohns disease. Clin Kidney J. 2016;9:556-9.
7) Bitik B, Gonul, II, Haznedaroglu S, Goker B, Tufan A.
Granulomatous interstitial nephritis associated with Primary
Sjogrens syndrome. Z Rheumatol. 2017;76:458-60.
8) Inoue T, Sato T, Okada H, Kayano H, Watanabe Y, Kikuta T,
Tsuda M, Sueyoshi K, Takenaka T, Suzuki H. Granulomatous
interstitial nephritis in chronic lymphocytic leukaemia. Nephrol
Dial Transplant. 2010;25:4107-9.
9) Nasr SH, Shanafelt TD, Hanson CA, Fidler ME, Cornell LD, Sethi
S, Chaffee KG, Morris J, Leung N. Granulomatous interstitial
nephritis secondary to chronic lymphocytic leukemia/small
lymphocytic lymphoma. Ann Diagn Pathol. 2015;19:130-6.
10) Nasr SH, Koscica J, Markowitz GS, DAgati VD. Granulomatous
interstitial nephritis. Am J Kidney Dis. 2003;41:714-9.
11) Ogura M, Kagami S, Nakao M, Kono M, Kanetsuna Y, Hosoya T.
Fungal granulomatous interstitial nephritis presenting as acute
kidney injury diagnosed by renal histology including PCR assay.
Clin Kidney J. 2012;5:459-62.
12) Gupta P, Rana DS, Bhalla AK, Gupta A, Malik M, Gupta A,
Bhargava V. Renal failure due to granulomatous interstitial
nephritis in native and allograft renal biopsies: Experience from
a tertiary care hospital. Ren Fail. 2014;36:1468-70.
13) Sampathkumar K, Sooraj YS, Mahaldar AR, Ramakrishnan
M, Rajappannair A, Nalumakkal SV, Erode E. Granulomatous
interstitial nephritis due to tuberculosis-a rare presentation.
Saudi J Kidney Dis Transpl. 2009;20:842-5.
14) Enriquez R, Cabezuelo JB, Gonzalez C, Lacueva J, Teruel A,
Fernandez J, Arenas MD. Granulomatous interstitial nephritis
associated with hydrochlorothiazide/amiloride. Am J Nephrol.
1995;15:270-3.
15) Geevasinga N, Coleman PL, Roger SD. Rabeprazole-induced
acute interstitial nephritis. Nephrology. (Carlton) 2005;10:7-9.
16) Nadri Q, Althaf MM. Granulomatous tubulointerstitial nephritis
secondary to omeprazole. BMJ Case Rep. 2014;2014.
17) Jung K, Zeng X, Bilusic M. Nivolumab-associated acute
glomerulonephritis: A case report and literature review. BMC
Nephrol. 2016;17:188.
18) Schwarz A, Krause PH, Keller F, Offermann G, Mihatsch MJ.
Granulomatous interstitial nephritis after nonsteroidal antiinflammatory
drugs. Am J Nephrol. 1988;8:410-6.
19) Avgustin N, Kovac D, Kojc N, Mlinsek G, Lindic J. Acute
granulomatous interstitial nephritis and acute rejection in a
kidney transplant recipient after zoledronic acid therapy - a case
report and review of the literature. Clin Nephrol. 2017;88:97-100.
20) Islam S, Dubigeon MP, Guenel J. Acute and reversible interstitial
granulomatous nephropathy after treatment with captopril. Rev
Med Interne. 1990;11:231-3.
21) Goli R, Mukku KK, Raju SB, Uppin MS. Acute Ciprofloxacin-
Induced Crystal Nephropathy with Granulomatous Interstitial
Nephritis. Indian J Nephrol. 2017;27:231-3.
22) Hong S, Valderrama E, Mattana J, Shah HH, Wagner JD, Esposito
M, Singhal PC. Vancomycin-induced acute granulomatous
interstitial nephritis: Therapeutic options. Am J Med Sci. 2007;
334:296-300.
23) Korsten P, Sweiss NJ, Nagorsnik U, Niewold TB, Grone HJ,
Gross O, Muller GA. Drug-induced granulomatous interstitial
nephritis in a patient with ankylosing spondylitis during therapy
with adalimumab. Am J Kidney Dis. 2010;56:e17-21.
24) Sandys V, Moloney B, Lane L, Qazi J, Doyle B, Barry M, Leavey
S, Conlon P. Granulomatous interstitial nephritis secondary to
adalimumab therapy. Clin Kidney J. 2018;11:219-21.
25) Borrego Utiel FJ, Luque Barona R, Perez Del Barrio P, Borrego
Hinojosa J, Ramirez Tortosa C. Acute Kidney Injury due to
granulomatous interstitial nephritis induced by tramadol
administration. Nefrologia. 2018;38:227-8.
26) Chu GJ, Henderson C, Evans L, Howlin K, Murad A. Chronic
granulomatous interstitial nephritis and urothelial metaplasia
associated with ritonavir-boosted atazanavir: A case study and
literature review. Pathology. 2018;50:565-8.
27) Varghese V, Rodriguez R, Self S, Velez JCQ. Atazanavir Crystal-
Induced Chronic Granulomatous Interstitial Nephritis. Kidney
Int Rep. 2020;5:1106-10.
28) Bottlaender L, Breton AL, de Laforcade L, Dijoud F, Thomas L,
Dalle S. Acute interstitial nephritis after sequential ipilumumab
- nivolumab therapy of metastatic melanoma. J Immunother
Cancer. 2017;5:57.
29) Oliveira B, Jayawardene S, Shah S. Single-centre experience of
granulomatous interstitial nephritis-time for a new approach?
Clin Kidney J. 2017;10:249-54.
30) Shah KK, Pritt BS, Alexander MP. Histopathologic review of
granulomatous inflammation. J Clin Tuberc Other Mycobact
Dis. 2017;7:1-12.
31) Bijol V, Mendez GP, Nose V, Rennke HG. Granulomatous
interstitial nephritis: A clinicopathologic study of 46 cases from a
single institution. Int J Surg Pathol. 2006;14:57-63.
32) Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial
nephritis. Clin J Am Soc Nephrol. 2007;2:222-30.
33) KDIGO clinical practice guideline for acute kidney injury.
Kidney Int Suppl. 2012;2:1-138.
34) Jennette JC. Rapidly progressive crescentic glomerulonephritis.
Kidney Int. 2003;63:1164-77.
35) Grossfeld GD, Wolf JS Jr, Litwan MS, Hricak H, Shuler CL, Agerter
DC, Carroll PR. Asymptomatic microscopic hematuria in adults:
Summary of the AUA best practice policy recommendations. Am
Fam Physician. 2001;63:1145-54.
36) Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita
K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition,
classification, and prognosis of chronic kidney disease: A KDIGO
Controversies Conference report. Kidney Int. 2011;80:17-28.
37) Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A,
Mamlouk O, Motwani SS, Murakami N, Herrmann SM,
Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan
A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB,
Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson
DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL,
Sise ME, Leaf DE. Clinical Features and Outcomes of Immune
Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J
Am Soc Nephrol. 2020;31:435-46.
38) Zammouri A, Barbouch S, Najjar M, Aoudia R, Jaziri F, Kaaroud
H, Hedri H, Abderrahim E, Goucha R, Hamida FB, Harzallah
A, Abdallah TB. Tubulointerstitial nephritis due to sarcoidosis:
Clinical, laboratory, and histological features and outcome in a
cohort of 24 patients. Saudi J Kidney Dis Transpl. 2019;30:1276-
84)
39) Zajjari Y, Azizi M, Bahadi A, Montasser D, Aatif T, Alayoud A,
El Kabbaj D. Granulomatous interstitial nephritis in the military
hospital of Morocco: Causes and outcomes. Saudi J Kidney Dis
Transpl. 2020;31:589-96.
40) Bajema IM, Hagen EC, van der Woude FJ, Bruijn JA. Wegeners
granulomatosis: A meta-analysis of 349 literary case reports. J
Lab Clin Med. 1997;129:17-22.
41) Unlu M, Kiremitci S, Ensari A, Ozluk Y, Kilicaslan I, Ozdemir
BH, Ates D, Ertoy Baydar D, Gonul, II, Memis L, Sarsik B, Sen S,
Akkaya B, Orhan D, Gonlusen G, Ellidokuz H, Ada S, Cavdar C,
Akagun T, Kamali S, Aksu K, Yazisiz V, Paydas S, Soylu A, Sarioglu
S. Pauci-immune necrotizing crescentic glomerulonephritis with
crescentic and full moon extracapillary proliferation: Clinicopathologic
correlation and follow-up study. Pathol Res Pract.
2013;209:75-82.
42) Eastwood JB, Corbishley CM, Grange JM. Tuberculosis and the
kidney. J Am Soc Nephrol. 2001;12:1307-14.
43) Agrawal V, Kaul A, Prasad N, Sharma K, Agarwal V. Etiological
diagnosis of granulomatous tubulointerstitial nephritis in the
tropics. Clin Kidney J. 2015;8:524-30.
44) Larsen CP, Moreira RK, Hennigar RA, Bijol V. Kidney biopsy
findings in a patient with fever, bilateral pulmonary infiltrates,
and acute renal failure. Am J Kidney Dis. 2008;51:524-9.
45) Davidson B, Nel D, Jones ESW, Manning K, Spies R, Bohmer R,
Omar A, Ash S, Wearne N. Granulomatous interstitial nephritis
on renal biopsy in human immunodeficiency virus positive
patients: Prevalence and causes in Cape Town, South Africa.
Nephrology. (Carlton) 2019;24:681-8.
46) Karmakar S, Basu K, Sengupta M, Sircar D, Roychowdhury A.
Granulomatous Interstitial Nephritis - A Series of Six Cases.
Indian J Nephrol. 2020;30:26-8.
47) Farris AB, Ellis CL, Rogers TE, Chon WJ, Chang A, Meehan SM.
Renal allograft granulomatous interstitial nephritis: Observations
of an uncommon injury pattern in 22 transplant recipients. Clin
Kidney J. 2017;10:240-8.
48) Vargas F, Gedalia A, Craver RD, Matti Vehaskari V. Recurrence
of granulomatous interstitial nephritis in transplanted kidney.
Pediatr Transplant. 2010;14:e54-7.
49) Teranishi J, Hattori Y, Mochizuki T, Kawahara T, Makiyama K,
Uemura H. Effective Treatment With Everolimus for Recurrent
Granulomatous Interstitial Nephritis in a Renal Transplant
Recipient: A Case Report. Transplant Proc. 2016;48:946-8.
50) Murtaza A, Ali H, Nair B, Ahmed AK. Recurrence of
Tubulointerstitial Nephritis Without Uveitis, in a Patient with
Previous Tubulointerstitial Nephritis and Uveitis Syndrome
After Transplant. Exp Clin Transplant. 2018;16:216-8.
51) Onyekpe I, Shenoy M, Denley H, Riad H, Webb NJ. Recurrent
tubulointerstitial nephritis and uveitis syndrome in a renal
transplant recipient. Nephrol Dial Transplant. 2011;26:3060-2.
52) Khaira A, Bagchi S, Sharma A, Mukund A, Mahajan S, Bhowmik
D, Dinda AK, Agarwal SK. Renal allograft tuberculosis: Report
of three cases and review of literature. Clin Exp Nephrol.
2009;13:392-6.
53) Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M,
Callard P, Ronco P, Rondeau E, Fain O. Renal granulomatoses:
A retrospective study of 40 cases and review of the literature.
Medicine. (Baltimore) 2007;86:170-80.
54) Mignon F, Mery JP, Mougenot B, Ronco P, Roland J, Morel-
Maroger L. Granulomatous interstitial nephritis. Adv Nephrol
Necker Hosp. 1984;13:219-45.
55) Naidu GD, Ram R, Swarnalatha G, Uppin M, Prayaga AK,
Dakshinamurty KV. Granulomatous interstitial nephritis: Our
experience of 14 patients. Indian J Nephrol. 2013;23:415-8.
56) Viero RM, Cavallo T: Granulomatous interstitial nephritis. Hum
Pathol. 1995;26:1347-53.
57) Alsaad KO, Tobar A, Belanger E, Ahmad M, Cattran DC,
Herzenberg AM. Late-onset acute haemorrhagic necrotizing
granulomatous adenovirus tubulointerstitial nephritis in a renal
allograft. Nephrol Dial Transplant. 2007;22:1257-60.
58) al-Sulaiman MH, Dhar JM, al-Hasani MK, Haleem A, al-Khader
A. Tuberculous interstitial nephritis after kidney transplantation.
Transplantation. 1990;50:162-4.
59) Asim M, Chong-Lopez A, Nickeleit V. Adenovirus infection of a
renal allograft. Am J Kidney Dis. 2003;41:696-701.
60) Aouizerate J, Matignon M, Kamar N, Thervet E, Randoux
C, Moulin B, Raffray L, Buchler M, Villar E, Mahevas M,
Desvaux D, Dahan K, Diet C, Audard V, Lang P, Grimbert P.
Renal transplantation in patients with sarcoidosis: A French
multicenter study. Clin J Am Soc Nephrol. 2010;5:2101-8.
61) Baden LR, Digumarthy SR, Guimaraes AS, Branda JA. Case
records of the Massachusetts General Hospital. Case 35-
2009. A 60-year-old male renal-transplant recipient with renal
insufficiency, diabetic ketoacidosis, and mental-status changes.
N Engl J Med. 2009;361:1980-9.
62) Bagnasco SM, Subramanian AK, Desai NM. Fungal infection
presenting as giant cell tubulointerstitial nephritis in kidney
allograft. Transpl Infect Dis. 2012;14:288-91.
63) Barraclough K, Oliver K, Playford EG, Preston J, Campbell S,
Johnson DW, Hawley C, Mudge D, van Eps C, Isbel N. Lifethreatening
adenovirus infection in a kidney transplant recipient.
NDT Plus. 2009;2:250-3.
64) Brown JH, Jos V, Newstead CG, Lawler W. Sarcoid-like
granulomata in a renal transplant. Nephrol Dial Transplant.
1992;7:173.
65) Gaspert A, Luthi B, Mueller NJ, Bossart W, Heim A, Wuthrich
RP, Fehr T. Subacute allograft failure with dysuria and hematuria
in a kidney transplant recipient. Am J Kidney Dis. 2009;54:154-8.
66) Gonçalves AR, Caetano MA, Paula FJ, Ianhez LE, Saldanha LB,
Sabbaga E. Tuberculous interstitial granulomatous nephritis
in renal transplants: Report of three cases. Transplant Proc.
1992;24:1911.
67) Hatlen T, Mroch H, Tuttle K, Ojogho O, Rooney M, Desmond S,
Bani-Hani S. Disseminated Adenovirus Nephritis After Kidney
Transplantation. Kidney Int Rep. 2018;3:19-23.
68) Hotta K, Fukasawa Y, Sasaki H, Seki T, Togashi M, Harada H.
Granulomatous tubulointerstitial nephritis in a renal allograft:
Three cases report and review of literature. Clin Transplant.
2012;26 Suppl 24:70-5.
69) Josephson MA, Chiu MY, Woodle ES, Thistlethwaite JR, Haas
M. Drug-induced acute interstitial nephritis in renal allografts:
Histopathologic features and clinical course in six patients. Am J
Kidney Dis. 1999;34:540-8.
70) Kukura S, Viklicky O, Lacha J, Voska L, Honsova E, Teplan V.
Recurrence of sarcoidosis in renal allograft during pregnancy.
Nephrol Dial Transplant. 2004;19:1640-2.
71) Lachiewicz AM, Cianciolo R, Miller MB, Derebail VK. Adenovirus
causing fever, upper respiratory infection, and allograft nephritis
complicated by persistent asymptomatic viremia. Transpl Infect
Dis. 2014;16:648-52.
72) Lapasia JB, Kambham N, Busque S, Tan JC. Renal allograft
granulomas in the early post-transplant period. NDT Plus.
2010;3:397-401.
73) Lorimer I, Botha J, Pontin AR, Pascoe MD, Kahn D. Tuberculosis
isolated to the renal allograft. Transpl Infect Dis. 1999;1:83-6.
74) Meehan SM, Josephson MA, Haas M. Granulomatous
tubulointerstitial nephritis in the renal allograft. Am J Kidney
Dis. 2000;36:E27.
75) Ozdemir BH, Sar A, Uyar P, Suren D, Demirhan B, Haberal M.
Posttransplant tubulointerstitial nephritis: Clinicopathological
correlation. Transplant Proc. 2006;38:466-9.
76) Parasuraman R, Zhang PL, Samarapungavan D, Rocher L,
Koffron A. Severe necrotizing adenovirus tubulointerstitial
nephritis in a kidney transplant recipient. Case Rep Transplant.
2013;2013:969186.
77) Park UJ, Hyun SK, Kim HT, Cho WH, Han SY. Successful
treatment of disseminated adenovirus infection with ribavirin
and intravenous immunoglobulin in an adult renal transplant
recipient: A case report. Transplant Proc. 2015;47:791-3.
78) Shen SY, Hall-Craggs M, Posner JN, Shabazz B. Recurrent
sarcoid granulomatous nephritis and reactive tuberculin skin test
in a renal transplant recipient. Am J Med. 1986;80:699-702.
79) Storsley L, Gibson IW. Adenovirus interstitial nephritis and
rejection in an allograft. J Am Soc Nephrol. 2011;22:1423-7.
80) Sujeet K, Vasudev B, Desai P, Bellizzi J, Novoa-Takara L, He C,
El-Meanawy A. Acute kidney injury requiring dialysis secondary
to adenovirus nephritis in renal transplant recipient. Transpl
Infect Dis. 2011;13:174-7.
81) Tse KC, Chan TM, Wong SS, Chan KW, Lam MF, Chan KH,
Li FK, Choy BY, Lai KN. Granulomatous interstitial nephritis
of the allograft kidney associated with rhodococcal pulmonary
infection. Nephrol Dial Transplant. 2004;19:486-90.
82) Varma MC, Kushner YB, Ko DS, Kawai T, Martins PN, Kaur
P, Markmann JF, Kotton CN. Early onset adenovirus infection
after simultaneous kidney-pancreas transplant. Am J Transplant.
2011;11:623-7.